X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (213) 213
oncology (148) 148
male (127) 127
female (118) 118
middle aged (117) 117
adult (104) 104
aged (93) 93
cancer (56) 56
kidney neoplasms - drug therapy (56) 56
carcinoma, renal cell - drug therapy (54) 54
hematology (52) 52
index medicus (47) 47
antineoplastic agents - therapeutic use (36) 36
treatment outcome (36) 36
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
therapy (35) 35
interleukin-2 (34) 34
interleukin-2 - therapeutic use (33) 33
aged, 80 and over (32) 32
kidney neoplasms - pathology (32) 32
antineoplastic agents - adverse effects (28) 28
interleukin-2 - administration & dosage (27) 27
medicine & public health (27) 27
immunotherapy (25) 25
renal cell carcinoma (24) 24
carcinoma, renal cell - pathology (22) 22
interleukin-2 - adverse effects (22) 22
antineoplastic agents - administration & dosage (21) 21
carcinoma, renal cell - mortality (21) 21
chemotherapy (20) 20
drug administration schedule (20) 20
kidney neoplasms - mortality (20) 20
neoplasm metastasis (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
immunology (19) 19
interferon-alpha (19) 19
interferon-alpha - administration & dosage (19) 19
carcinoma, renal cell (18) 18
survival rate (18) 18
carcinoma, renal cell - secondary (17) 17
internal medicine (17) 17
survival analysis (17) 17
disease-free survival (16) 16
prognosis (16) 16
adolescent (15) 15
care and treatment (15) 15
dose-response relationship, drug (15) 15
infusions, intravenous (15) 15
medicine, research & experimental (15) 15
metastasis (15) 15
carcinoma (14) 14
kidney cancer (14) 14
melanoma - drug therapy (14) 14
recombinant interleukin-2 (14) 14
remission induction (14) 14
trial (14) 14
combination (13) 13
follow-up studies (13) 13
interferon-alpha - therapeutic use (13) 13
kidney neoplasms - therapy (13) 13
neoplasms - drug therapy (13) 13
renal-cell carcinoma (13) 13
survival (13) 13
toxicity (13) 13
melanoma (12) 12
research (12) 12
animals (11) 11
article (11) 11
combined modality therapy (11) 11
drug therapy (11) 11
expression (11) 11
interferon (11) 11
melanoma - secondary (11) 11
niacinamide - analogs & derivatives (11) 11
sorafenib (11) 11
carcinoma, renal cell - therapy (10) 10
leukemia (10) 10
pathology (10) 10
pharmacology & pharmacy (10) 10
renal cell cancer (10) 10
risk factors (10) 10
antimitotic agents (9) 9
antineoplastic agents (9) 9
antineoplastic agents - pharmacology (9) 9
bevacizumab (9) 9
blood (9) 9
clinical trials (9) 9
cytokines (9) 9
interferon-alpha - adverse effects (9) 9
medicine, general & internal (9) 9
melanoma - therapy (9) 9
neoplasms - therapy (9) 9
patient outcomes (9) 9
phase-ii trial (9) 9
time factors (9) 9
activated killer cells (8) 8
acute myeloid-leukemia (8) 8
adoptive immunotherapy (8) 8
blood transfusion (8) 8
disease progression (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1990, ISBN 0849362482, v.
Book
2013, 5th ed., ISBN 9781461437635, xix, 1431
Neoplastic Diseases of the Blood integrates the history, epidemiology, pathology, pathophysiology, and therapeutics of modern neoplastic hematopathology. The... 
Hematologic Neoplasms | Lymphoma | Leukemia | Multiple Myeloma | Clinical & internal medicine | Blood | Lymphomas | Multiple myeloma | Oncology | Internal Medicine | Medicine & Public Health | Hematology | Hematological oncology
Book
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 9/2018, Volume 67, Issue 9, pp. 1473 - 1474
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00262-018-2208-y 
Oncology | Cancer Research | Immunology | Medicine & Public Health | ONCOLOGY | IMMUNOLOGY | Prognosis | Protein Kinase Inhibitors - therapeutic use | Humans | Immunotherapy | Kidney Neoplasms - immunology | Carcinoma, Renal Cell - therapy | Carcinoma, Renal Cell - immunology | Disease Progression | Kidney Neoplasms - therapy | Semantics
Journal Article
2003, 4th ed., ISBN 0521791367, xvii, 1196 p., [12] p. of plates
Book
The Oncologist, ISSN 1083-7159, 09/2018, Volume 23, Issue 9, pp. e107 - e107
As new immunotherapy treatment options become available, one must focus on the goals of extending survival and of potential cure. 
ONCOLOGY | RENAL-CELL CARCINOMA | Letters to the Editor
Journal Article
Journal of Investigative Medicine, ISSN 1081-5589, 01/2019, Volume 67, Issue 1, pp. 1 - 10
Renal cell cancer (RCC) (epithelial carcinoma of the kidney) represents 2%-4% of newly diagnosed adult tumors. Over the past 2 decades, RCC has been better... 
kidney diseases | MEDICINE, RESEARCH & EXPERIMENTAL | CYTOREDUCTIVE NEPHRECTOMY | MEDULLARY CARCINOMA | TUBULOCYSTIC CARCINOMA | ADJUVANT SUNITINIB | RADICAL NEPHRECTOMY | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA | HIGH-RISK | BRAIN METASTASES | TARGETED AGENTS | DOUBLE-BLIND
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 7_suppl, pp. 586 - 586
Journal Article
03/2018, 6th ed. 2018, ISBN 3319642626, 1323
This book integrates the history, epidemiology, pathology, pathophysiology, and therapeutics of modern neoplastic hematopathology. Coerage includes Chronic... 
Medicine & Public Health | Hematology | Oncology | CLL | Chronic Myeloid Leukemia | Non-Hodgkin Lymphoma | Hematological Neoplasms | Acute Promyelocytic Leukemia | Multiple Myeloma
eBook
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 6_suppl, pp. 575 - 575
575 Background: The benefit of vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) as adjuvant therapy for RCC remains a subject of... 
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 10/2019, Volume 25, Issue 20, pp. 6098 - 6106
Purpose: The use of VEGFR TKIs for the adjuvant treatment of renal cell carcinoma (RCC) remains controversial. We investigated the effects of adjuvant VEGFR... 
BIOMARKERS | PAZOPANIB | ONCOLOGY | HIGH-RISK | SUNITINIB | RECEPTOR | HYPERTENSION | SORAFENIB | CANCER | EXPRESSION | NEPHRECTOMY | Index Medicus
Journal Article
The Journal of urology, ISSN 0022-5347, 10/2019, p. 101097JU0000000000000588
We describe what is to our knowledge a novel classification system for local recurrence after surgery of renal cell carcinoma. We assessed its prognostic... 
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 08/2019, Volume 37, Issue 23, pp. 2062 - 2062
PURPOSETo validate currently used recurrence prediction models for renal cell carcinoma (RCC) by using prospective data from the ASSURE (ECOG-ACRIN E2805;... 
RADICAL NEPHRECTOMY | SURVIVAL | PLACEBO | ONCOLOGY | OUTCOME PREDICTION | HIGH-RISK | NOMOGRAM | CELL CARCINOMA | ADJUVANT SUNITINIB
Journal Article
Investigational new drugs, ISSN 0167-6997, 01/2020
Preclinical studies suggest that histone deacetylase (HDAC) inhibitors may restore tumor sensitivity to retinoids and have synergistic anti-tumor activity when... 
Journal Article
Leukemia Research, ISSN 0145-2126, 04/2018, Volume 67, pp. 39 - 44
There is mounting evidence that Langerhans cell histiocytosis (LCH) and acute myeloid leukemia (AML) are hematopoietic neoplasms that arise from the same... 
Idiopathic myelofibrosis | Genetic | Langerhans cell histiocytosis | Acute myeloid leukemia | Familial | EOSINOPHILIC GRANULOMA | ADULT | ETOPOSIDE | MALIGNANCY | LETTERER-SIWE DISEASE | ONCOLOGY | ANTICIPATION | SECONDARY LEUKEMIA | HEMATOLOGY | ASSOCIATION | ACUTE PROMYELOCYTIC LEUKEMIA
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e21005 - e21005
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.